Molecular Neurobiology

, Volume 48, Issue 2, pp 353–362 | Cite as

Food, Nutrigenomics, and Neurodegeneration—Neuroprotection by What You Eat!

  • Ashraf Virmani
  • Luigi Pinto
  • Zbigniew Binienda
  • Syed Ali
Article

Abstract

Diet in human health is no longer simple nutrition, but in light of recent research, especially nutrigenomics, it is linked via evolution and genetics to cell health status capable of modulating apoptosis, detoxification, and appropriate gene response. Nutritional deficiency and disease especially lack of vitamins and minerals is well known, but more recently, epidemiological studies suggest a role of fruits and vegetables, as well as essential fatty acids and even red wine (French paradox), in protection against disease. In the early 1990s, various research groups started considering the use of antioxidants (e.g., melatonin, resveratrol, green tea, lipoic acid) and metabolic compounds (e.g., nicotinamide, acetyl-l-carnitine, creatine, coenzyme Q10) as possible candidates in neuroprotection. They were of course considered on par with snake oil salesman (women) at the time. The positive actions of nutritional supplements, minerals, and plant extracts in disease prevention are now mainstream and commercial health claims being made are subject to regulation in most countries. Apart from efficacy and finding, the right dosages, the safety, and especially the level of purification and lack of contamination are all issues that are important as their use becomes widespread. From the mechanistic point of view, most of the time these substances replenish the body’s deficiency and restore normal function. However, they also exert actions that are not sensu stricto nutritive and could be considered pharmacological especially that, at times, higher intake than recommended (RDA) is needed to see these effects. Free radicals and neuroinflammation processes underlie many neurodegenerative conditions, even Parkinson’s disease and Alzheimer’s disease. Curcumin, carotenoids, acetyl-l-carnitine, coenzyme Q10, vitamin D, and polyphenols and other nutraceuticals have the potential to target multiple pathways in these conditions. In summary, augmenting neuroprotective pathways using diet and finding new natural substances that can be more efficacious, i.e., induction of health-promoting genes and reduction of the expression of disease-promoting genes, could be incorporated into neuroprotective strategies of the future.

Keywords

Nutrition Nutrigenomics Neuroprotection Nutraceuticals l-Carnitine Polyphenols Vitamins Coenzyme Q10 

References

  1. 1.
    Virmani A, Binienda Z, Ali S, Gaetani F (2006) Links between nutrition, drug abuse, and the metabolic syndrome. Ann N Y Acad Sci 1074:303–14CrossRefPubMedGoogle Scholar
  2. 2.
    Joseph J, Cole G, Head E, Ingram D (2009) Nutrition, brain aging, and neurodegeneration. J Neurosci 29:12795–801CrossRefPubMedGoogle Scholar
  3. 3.
    Lillycrop KA, Burdge GC (2012) Epigenetic mechanisms linking early nutrition to long term health. Best Pract Res Clin Endocrinol Metab 26:667–76CrossRefPubMedGoogle Scholar
  4. 4.
    Williams M (2011) Qualitative pharmacology in a quantitative world: diminishing value in the drug discovery process. Curr Opin Pharmacol 11:496–500CrossRefPubMedGoogle Scholar
  5. 5.
    Deitrich R, Zimatkin S, Pronko S (2006) Oxidation of ethanol in the brain and its consequences. Alcohol Res Health 29:266–73PubMedGoogle Scholar
  6. 6.
    Jukes TH (1989) The prevention and conquest of scurvy, beri-beri, and pellagra. Prev Med 18:877–83CrossRefPubMedGoogle Scholar
  7. 7.
    Boeing H, Bechthold A, Bub A, Ellinger S, Haller D, Kroke A, Leschik-Bonnet E, Müller MJ, Oberritter H, Schulze M, Stehle P, Watzl B (2012) Critical review: vegetables and fruit in the prevention of chronic diseases. Eur J Nutr 51:637–63CrossRefPubMedGoogle Scholar
  8. 8.
    NIH Office of Dietary Supplements (2012) Dietary supplements: what you need to know NIH Office of Dietary Supplements Web site. Accessed at ods.od.nih.gov/HealthInformation/DS_WhatYouNeedToKnow.aspx. Accessed 17 June 2011
  9. 9.
    Gold LS, Slone TH, Ranking MS (1999) Possible toxic hazards of dietary supplements compared to other natural and synthetic substances. Testimony to the FDA, Docket No. 99N-1174Google Scholar
  10. 10.
    Kelsey NA, Wilkins HM, Linseman DA (2010) Nutraceutical antioxidants as novel neuroprotective agents. Molecules 15:7792–814CrossRefPubMedGoogle Scholar
  11. 11.
    Roberts RA, Laskin DL, Smith CV, Robertson FM, Allen EM, Doorn JA, Slikker W (2009) Nitrative and oxidative stress in toxicology and disease. Toxicol Sci 112:4–16CrossRefPubMedGoogle Scholar
  12. 12.
    Schroeder EK, Kelsey NA, Doyle J, Breed E, Bouchard RJ, Loucks FA, Harbison RA, Linseman DA (2009) Green tea epigallocatechin 3-gallate accumulates in mitochondria and displays a selective antiapoptotic effect against inducers of mitochondrial oxidative stress in neurons. Antioxid Redox Signal 11:469–80CrossRefPubMedGoogle Scholar
  13. 13.
    Wagner AE, Ernst IM, Birringer M, Sancak O, Barella L, Rimbach G (2012) A combination of lipoic acid plus coenzyme Q10 induces PGC1a, a master switch of energy metabolism, improves stress response, and increases cellular glutathione levels in cultured C2C12 skeletal muscle cells. Oxid Med Cell Longev 2012:835970CrossRefPubMedGoogle Scholar
  14. 14.
    Matsubara E, Bryant-Thomas T, Pacheco Quinto J, Henry TL, Poeggeler B, Herbert D, Cruz-Sanchez F, Chyan YJ, Smith MA, Perry G, Shoji M, Abe K, Leone A, Grundke-Ikbal I, Wilson GL, Ghiso J, Williams C, Refolo LM, Pappolla MA, Chain DG, Neria E (2003) Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer’s disease. J Neurochem 85:1101–8CrossRefPubMedGoogle Scholar
  15. 15.
    Fischer A, Schmelzer C, Rimbach G, Niklowitz P, Menke T, Döring F (2011) Association between genetic variants in the coenzyme Q10 metabolism and coenzyme Q10 status in humans. BMC Res Notes 21:245CrossRefGoogle Scholar
  16. 16.
    Lappas M, Mitton A, Lim R, Barker G, Riley C, Permezel M (2011) SIRT1 is a novel regulator of key pathways of human labor. Biol Reprod 84:167–78CrossRefPubMedGoogle Scholar
  17. 17.
    Calabrese V, Ravagna A, Colombrita C, Scapagnini G, Guagliano E, Calvani M, Butterfield DA, Giuffrida Stella AM (2005) Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: involvement of the transcription factor Nrf2. J Neurosci Res 79:509–21CrossRefPubMedGoogle Scholar
  18. 18.
    Hardy TM, Tollefsbol TO (2011) Epigenetic diet: impact on the epigenome and cancer. Epigenomics 3:503–18CrossRefPubMedGoogle Scholar
  19. 19.
    Alam SE, Singh RB, Gupta S, Dherange P, De Meester F, Wilczynska A, Dharwadkar S, Wilson D, Hungin P (2012) Nutritional aspects of epigenetic inheritance. Can J Physiol Pharmacol 90:989–94CrossRefPubMedGoogle Scholar
  20. 20.
    Ling C, Groop L (2009) Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes 58:2718–25CrossRefPubMedGoogle Scholar
  21. 21.
    Troen BR (2003) The biology of aging. Mt Sinai J Med 70:3–22PubMedGoogle Scholar
  22. 22.
    Chung S, Yao H, Caito S, Hwang JW, Arunachalam G, Rahman I (2010) Regulation of SIRT1 in cellular functions: role of polyphenols. Arch Biochem Biophys 501:79–90CrossRefPubMedGoogle Scholar
  23. 23.
    Duan W, Ross CA (2010) Potential therapeutic targets for neurodegenerative diseases: lessons learned from calorie restriction. Curr Drug Targets 11:1281–92CrossRefPubMedGoogle Scholar
  24. 24.
    Virmani A, Ali SF, Binienda ZK (2010) Neuroprotective strategies in drug abuse-evoked encephalopathy. Ann N Y Acad Sci 1199:52–68CrossRefPubMedGoogle Scholar
  25. 25.
    Lee HH, Yang LL, Wang CC, Hu SY, Chang SF, Lee YH (2003) Differential effects of natural polyphenols on neuronal survival in primary cultured central neurons against glutamate- and glucose deprivation-induced neuronal death. Brain Res 986:103–13CrossRefPubMedGoogle Scholar
  26. 26.
    Braidy N, Grant R, Adams S, Guillemin GJ (2010) Neuroprotective effects of naturally occurring polyphenols on quinolinic acid-induced excitotoxicity in human neurons. FEBS J 277:368–82CrossRefPubMedGoogle Scholar
  27. 27.
    Renaud S, de Lorgeril M (1992) Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339:1523–6CrossRefPubMedGoogle Scholar
  28. 28.
    Ankarcrona M, Dypbukt JM, Bonfoco E, Zhivotovsky B, Orrenius S, Lipton SA, Nicotera P (1995) Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron 15:961–73CrossRefPubMedGoogle Scholar
  29. 29.
    Campos-Esparza MR, Sánchez-Gómez MV, Matute C (2009) Molecular mechanisms of neuroprotection by two natural antioxidant polyphenols. Cell Calcium 45:358–68CrossRefPubMedGoogle Scholar
  30. 30.
    Singleton RH, Yan HQ, Fellows-Mayle W, Dixon CE (2010) Resveratrol attenuates behavioral impairments and reduces cortical and hippocampal loss in a rat controlled cortical impact model of traumatic brain injury. J Neurotrauma 27:1091–9CrossRefPubMedGoogle Scholar
  31. 31.
    Schinder AF, Olson EC, Spitzer NC, Montal M (1996) Mitochondrial dysfunction is a primary event in glutamate neurotoxicity. J Neurosci 16:6125–33PubMedGoogle Scholar
  32. 32.
    Tenneti L, Lipton SA (2000) Involvement of activated caspase-3-like proteases in N-methyl-d-aspartate-induced apoptosis in cerebrocortical neurons. J Neurochem 74:134–42CrossRefPubMedGoogle Scholar
  33. 33.
    Tenneti L, D’Emilia DM, Troy CM, Lipton SA (1998) Role of caspases in N-methyl-d-aspartate-induced apoptosis in cerebrocortical neurons. J Neurochem 71:946–59CrossRefPubMedGoogle Scholar
  34. 34.
    Hirashima Y, Kurimoto M, Nogami K, Endo S, Saitoh M, Ohtani O, Nagata T, Muraguchi A, Takaku A (1999) Correlation of glutamate-induced apoptosis with caspase activities in cultured rat cerebral cortical neurons. Brain Res 849:109–18CrossRefPubMedGoogle Scholar
  35. 35.
    Brecht S, Gelderblom M, Srinivasan A, Mielke K, Dityateva G, Herdegen T (2001) Caspase-3 activation and DNA fragmentation in primary hippocampal neurons following glutamate excitotoxicity. Brain Res Mol Brain Res 94:25–34CrossRefPubMedGoogle Scholar
  36. 36.
    Gottlieb M, Leal-Campanario R, Campos-Esparza MR, Sánchez-Gómez MV, Alberdi E, Arranz A, Delgado-García JM, Gruart A, Matute C (2006) Neuroprotection by two polyphenols following excitotoxicity and experimental ischemia. Neurobiol Dis 23:374–86CrossRefPubMedGoogle Scholar
  37. 37.
    Mercer LD, Kelly BL, Horne MK, Beart PM (2005) Dietary polyphenols protect dopamine neurons from oxidative insults and apoptosis: investigations in primary rat mesencephalic cultures. Biochem Pharmacol 69:339–45CrossRefPubMedGoogle Scholar
  38. 38.
    Vafeiadou K, Vauzour D, Spencer JP (2007) Neuroinflammation and its modulation by flavonoids. Endocr Metab Immune Disord Drug Targets 7:211–24CrossRefPubMedGoogle Scholar
  39. 39.
    Mandel SA, Avramovich-Tirosh Y, Reznichenko L, Zheng H, Weinreb O, Amit T, Youdim MB (2005) Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway. Neurosignals 14:46–60CrossRefPubMedGoogle Scholar
  40. 40.
    Svilar D, Goellner EM, Almeida KH, Sobol RW (2011) Base excision repair and lesion-dependent subpathways for repair of oxidative DNA damage. Antioxid Redox Signal 14:2491–507CrossRefPubMedGoogle Scholar
  41. 41.
    Fukui H, Moraes CT (2008) The mitochondrial impairment, oxidative stress and neurodegeneration connection: reality or just an attractive hypothesis? Trends Neurosci 31:251–6CrossRefPubMedGoogle Scholar
  42. 42.
    Fukui H, Moraes CT (2009) Mechanisms of formation and accumulation of mitochondrial DNA deletions in aging neurons. Hum Mol Genet 18:1028–36CrossRefPubMedGoogle Scholar
  43. 43.
    Virmani MA, Biselli R, Spadoni A, Rossi S, Corsico N, Calvani M, Fattorossi A, De Simone C, Arrigoni-Martelli E (1995) Protective actions of l-carnitine and acetyl-l-carnitine on the neurotoxicity evoked by mitochondrial uncoupling or inhibitors. Pharmacol Res 32:383–9CrossRefPubMedGoogle Scholar
  44. 44.
    Hauser DN, Hastings TG (2013) Mitochondrial dysfunction and oxidative stress in Parkinson’s disease and monogenic parkinsonism. Neurobiol Dis 51:35–42CrossRefPubMedGoogle Scholar
  45. 45.
    Pickrell AM, Fukui H, Moraes CT (2009) The role of cytochrome c oxidase deficiency in ROS and amyloid plaque formation. J Bioenerg Biomembr 41:453–6CrossRefPubMedGoogle Scholar
  46. 46.
    Mahad D, Ziabreva I, Lassmann H, Turnbull D (2008) Mitochondrial defects in acute multiple sclerosis lesions. Brain 131:1722–35CrossRefPubMedGoogle Scholar
  47. 47.
    Mahad D, Ziabreva I, Campbell G, Lax N, Hanson PS, Lassmann H, Turnbull DH (2009) Mitochondrial changes within axons in multiple sclerosis. Brain 132:1161–74CrossRefPubMedGoogle Scholar
  48. 48.
    Higgins GC, Beart PM, Shin YS, Chen MJ, Cheung NS, Nagley P (2010) Oxidative stress: emerging mitochondrial and cellular themes and variations in neuronal injury. J Alzheimers Dis 20:453–73Google Scholar
  49. 49.
    Lu F, Selak M, O’Connor J, Croul S, Lorenzana C, Butunoi C, Kalman B (2000) Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis. J Neurol Sci 177:95–103CrossRefPubMedGoogle Scholar
  50. 50.
    Kalman B, Leist TP (2003) A mitochondrial component of neurodegeneration in multiple sclerosis. Neuromolecular Med 3:147–58CrossRefPubMedGoogle Scholar
  51. 51.
    Mao P, Reddy PH (2010) Is multiple sclerosis a mitochondrial disease? Biochim Biophys Acta 1802:66–79CrossRefPubMedGoogle Scholar
  52. 52.
    van Horssen J, Schreibelt G, Drexhage J, Hazes T, Dijkstra CD, van der Valk P, de Vries HE (2008) Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic Biol Med 45:1729–37CrossRefPubMedGoogle Scholar
  53. 53.
    Vladimirova O, O’Connor J, Cahill A, Alder H, Butunoi C, Kalman B (1998) Oxidative damage to DNA in plaques of MS brains. Mult Scler 4:413–8PubMedGoogle Scholar
  54. 54.
    Smith KJ, Kapoor R, Felts PA (1999) Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 9:69–92CrossRefPubMedGoogle Scholar
  55. 55.
    Bizzozero OA, DeJesus G, Callahan K, Pastuszyn A (2005) Elevated protein carbonylation in the brain white matter and gray matter of patients with multiple sclerosis. J Neurosci Res 81:687–95CrossRefPubMedGoogle Scholar
  56. 56.
    Qin J, Goswami R, Balabanov R, Dawson G (2007) Oxidized phosphatidylcholine is a marker for neuroinflammation in multiple sclerosis brain. J Neurosci Res 85:977–84CrossRefPubMedGoogle Scholar
  57. 57.
    Farinotti M, Vacchi L, Simi S, Di Pietrantonj C, Brait L, Filippini G (2012) Dietary interventions for multiple sclerosis. Cochrane Database Syst Rev 12, CD004192PubMedGoogle Scholar
  58. 58.
    Virmani A, Binienda Z (2004) Role of carnitine esters in brain neuropathology. Mol Aspects Med 25:533–4CrossRefPubMedGoogle Scholar
  59. 59.
    Ramassamy C (2006) Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur J Pharmacol 545:51–64CrossRefPubMedGoogle Scholar
  60. 60.
    Virmani A, Gaetani F, Binienda Z (2005) Effects of metabolic modifiers such as carnitines, coenzyme Q10, and PUFAs against different forms of neurotoxic insults: metabolic inhibitors, MPTP, and methamphetamine. Ann N Y Acad Sci 1053:183–91CrossRefPubMedGoogle Scholar
  61. 61.
    Topcu-Tarladacalisir Y, Kanter M, Uzal MC (2009) Role of l-carnitine in the prevention of seminiferous tubules damage induced by gamma radiation: a light and electron microscopic study. Arch Toxicol 83:735–46CrossRefPubMedGoogle Scholar
  62. 62.
    Gülçin I (2006) Antioxidant and antiradical activities of l-carnitine. Life Sci 78:803–11CrossRefPubMedGoogle Scholar
  63. 63.
    Calabrese V, Guagliano E, Sapienza M, Panebianco M, Calafato S, Puleo E, Pennisi G, Mancuso C, Butterfield DA, Stella AG (2007) Redox regulation of cellular stress response in aging and neurodegenerative disorders: role of vitagenes. Neurochem Res 32:757–73CrossRefPubMedGoogle Scholar
  64. 64.
    Suchitra MM, Ashalatha VL, Sailaja E, Rao AM, Reddy VS, Bitla AR, Sivakumar V, Rao PV (2011) The effect of l-carnitine supplementation on lipid parameters, inflammatory and nutritional markers in maintenance hemodialysis patients. Saudi J Kidney Dis Transpl 22:1155–9PubMedGoogle Scholar
  65. 65.
    Perez-De La Cruz V, Santamaria A (2007) Integrative hypothesis for Huntington’s disease: a brief review of experimental evidence. Physiol Res 56:513–26PubMedGoogle Scholar
  66. 66.
    Shen W, Liu K, Tian C, Yang L, Li X, Ren J, Packer L, Cotman CW, Liu J (2008) R-alpha-lipoic acid and acetyl-l-carnitine complementarily promote mitochondrial biogenesis in murine 3T3-L1 adipocytes. Diabetologia 51:165–74CrossRefPubMedGoogle Scholar
  67. 67.
    Silva-Adaya D, Pérez-De La Cruz V, Herrera-Mundo MN, Mendoza-Macedo K, Villeda-Hernández J, Binienda Z, Ali SF, Santamaría A (2008) Excitotoxic damage, disrupted energy metabolism, and oxidative stress in the rat brain: antioxidant and neuroprotective effects of l-carnitine. J Neurochem 105:677–89CrossRefPubMedGoogle Scholar
  68. 68.
    Beher D, Wu J, Cumine S, Kim KW, Lu SC, Atangan L, Wang M (2009) Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 74:619–24CrossRefPubMedGoogle Scholar
  69. 69.
    Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, Griffith D, Griffor M, Loulakis P, Pabst B, Qiu X, Stockman B, Thanabal V, Varghese A, Ward J, Withka J, Ahn K (2010) SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 285:8340–51CrossRefPubMedGoogle Scholar
  70. 70.
    Wareski P, Vaarmann A, Choubey V, Safiulina D, Liiv J, Kuum M, Kaasik A (2009) PGC-1{alpha} and PGC-1{beta} regulate mitochondrial density in neurons. J Biol Chem 284:21379–85CrossRefPubMedGoogle Scholar
  71. 71.
    Wang K, Lee I, Carlson G, Hood L, Galas D (2010) Systems biology and the discovery of diagnostic biomarkers. Dis Markers 28:199–207CrossRefPubMedGoogle Scholar
  72. 72.
    Buonaguro L, Pulendran B (2011) Immunogenomics and systems biology of vaccines. Immunol Rev 239:197–208CrossRefPubMedGoogle Scholar
  73. 73.
    Buonaguro L, Wang E, Tornesello ML, Buonaguro FM, Marincola FM (2011) Systems biology applied to vaccine and immunotherapy development. BMC Syst Biol 5:146CrossRefPubMedGoogle Scholar
  74. 74.
    Aderem A, Adkins JN, Ansong C, Galagan J, Kaiser S, Korth MJ, Law GL, McDermott JG, Proll SC, Rosenberger C, Schoolnik G, Katze MG (2011) A systems biology approach to infectious disease research: innovating the pathogen–host research paradigm. MBio 2:e00325–10CrossRefPubMedGoogle Scholar
  75. 75.
    Müller M, Kersten S (2003) Nutrigenomics: goals and strategies. Nat Rev Genet 4:315–22CrossRefPubMedGoogle Scholar
  76. 76.
    Kapka-Skrzypczak L, Niedzwiecka J, Cyranka M, Kruszewski MK, Skrzypczak M, Wojtyla A (2011) Nutrigenomics—perspectives of personalized nutrition. Pediatr Endocrinol Diabetes Metab 17:222–6PubMedGoogle Scholar
  77. 77.
    García-Cañas V, Simó C, León C, Cifuentes A (2010) Advances in nutrigenomics research: novel and future analytical approaches to investigate the biological activity of natural compounds and food functions. J Pharm Biomed Anal 51:290–304CrossRefPubMedGoogle Scholar
  78. 78.
    Raqib R, Cravioto R (2009) Nutrition, immunology, and genetics: future perspectives. Nutr Rev 67:S227–36CrossRefPubMedGoogle Scholar
  79. 79.
    Wittwer J, Rubio-Aliaga I, Hoeft B, Bendik I, Weber P, Daniel H (2011) Nutrigenomics in human intervention studies: current status, lessons learned and future perspectives. Mol Nutr Food Res 55:341–58CrossRefPubMedGoogle Scholar
  80. 80.
    Harrow J et al (2012) GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res 22:1760–74CrossRefPubMedGoogle Scholar
  81. 81.
    ENCODE Project Consortium, Bernstein BE, Birney E, Dunham I, Green ED, Gunter C, Snyder M (2012) An integrated encyclopedia of DNA elements in the human genome. Nature 489:57–74CrossRefPubMedGoogle Scholar
  82. 82.
    Trujillo E, Davis C, Milner J (2006) Nutrigenomics, proteomics, metabolomics, and the practice of dietetics. J Am Diet Assoc 106:403–13CrossRefPubMedGoogle Scholar
  83. 83.
    Madiraju P, Pande SV, Prentki M, Madiraju SR (2009) Mitochondrial acetylcarnitine provides acetyl groups for nuclear histone acetylation. Epigenetics 4:399–403CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York (outside the USA) 2013

Authors and Affiliations

  • Ashraf Virmani
    • 1
  • Luigi Pinto
    • 1
  • Zbigniew Binienda
    • 2
  • Syed Ali
    • 3
  1. 1.Research, Innovation and DevelopmentSigma-tau SpAPomeziaItaly
  2. 2.Neurophysiology Laboratory, Division of Neurotoxicology, National Center for Toxicological ResearchFood and Drug AdministrationJeffersonUSA
  3. 3.Neurochemistry Laboratory, Division of Neurotoxicology, National Center for Toxicological ResearchFood and Drug AdministrationJeffersonUSA

Personalised recommendations